share_log

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87

Moomoo 24/7 ·  Mar 11 07:51

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target from $81 to $87.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment